Texaphyrins: a new approach to drug development

被引:64
作者
Mody, TD
Sessler, JL
机构
[1] Pharmacycl Inc, Sunnyvale, CA 94085 USA
[2] Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA
关键词
texaphyrin; porphyrin; expanded porphyrin; motexafin gadolinium; motexafin lutetium; photodynamic therapy; photoangioplasty; photosensitizer; radiation sensitization; breast cancer; age-related macular degeneration;
D O I
10.1002/jpp.326
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The texaphyrins are prototypical metal-coordinating expanded porphyrins. They represent a burgeoning class of pharmacological agents that show promise for an array of medical applications. Currently, two different water-soluble lanthanide texaphyrins, namely motexafin gadolinium (Gd-Tex, 1) and motexafin lutetium (Lu-Tex, 2), are involved in multi-center clinical trials for a variety of indications. The first of these agents, XCYTRIN(R) (motexafin gadolinium) Injection, is being evaluated as a potential X-ray radiation enhancer in a randomized Phase III clinical trial in patients with brain metastases. The second, in various formulations, is being evaluated as a photosensitizer for use in: (i) the photodynamic treatment of recurrent breast cancer (LUTRIN(R) Injection; now in Phase IIb clinical trials); (ii) photoangioplastic reduction of atherosclerosis involving peripheral and coronary arteries (ANTRIN(R) Injection; now in Phase II and Phase I clinical trials, respectively); and (iii) light-based age-related macular degeneration (OPTRIN(R) Injection; currently under Phase II clinical evaluation), a vision-threatening disease of the retina. In this article, these developments, along with fundamental aspects of the underlying chemistry are reviewed. Copyright (C) 2001 John Wiley & Sons, Ltd.
引用
收藏
页码:134 / 142
页数:9
相关论文
共 86 条
  • [1] Metal complexes as photo- and radiosensitizers
    Ali, H
    van Lier, JE
    [J]. CHEMICAL REVIEWS, 1999, 99 (09) : 2379 - 2450
  • [2] Arbour JD, 1999, INVEST OPHTH VIS SCI, V40, pS401
  • [3] AULER H., 1942, Z. Krebsforsck, V53, P65, DOI 10.1007/BF01792783
  • [4] BEARD CJ, 1993, CANC PRINCIPLES PRAC, P2701
  • [5] Bellnier D A, 1996, J Clin Laser Med Surg, V14, P311
  • [6] Bonnett R, 1999, REV CONTEMP PHARMACO, V10, P1
  • [7] Structure and biodistribution relationships of photodynamic sensitizers
    Boyle, RW
    Dolphin, D
    [J]. PHOTOCHEMISTRY AND PHOTOBIOLOGY, 1996, 64 (03) : 469 - 485
  • [8] Brada Michael, 1995, Current Opinion in Oncology, V7, P214
  • [9] Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
  • [10] BROWN JM, 1989, INT J RADIAT ONCOL, V16, P987